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Focal increased radiopharmaceutical uptake in a lesion results in focal Hot 
Spots in the scans. This can occur in benign infective or inflammatory disorders 
and cancerous diseases as well. Comparison between malignant and benign lesions 
is important. The Hot spots can be classified into benign and malignant lesions by 
Spatial Scintimetry or Temporal Scintimetry. Spatial Scintimetry compares the 
uptake in the region of interest with the adjacent tissue or the unaffected contra-
lateral site. The quantitative indices are lesion/non lesion ratio, lesion/background 
activity and lesion to Bone ratio etc. The Temporal Scintimetry relies on the changes 
in the counts or uptake in the Hotspot lesion with reference to the dual point time 
of acquisition. The Hotspot in the bone scan can be classified using the quantitative 
index of retention ratio by Dr. V. Siva and Israel. In PET studies the focal hot spots 
can be differentiated into benign and malignant lesion using the dual phase PETCT 
evaluation using the Rong’s Retention ratio and Dr. V. Siva’s modified RRI values.
Keywords: radiopharmaceutical uptake, scintimetric characterization,  
spatial scintimetry, temporal scintimetry, quantitative indices
1. Introduction
The uptake of the Radiopharmaceuticals in the organ of interest makes the 
functional evaluation of that organ feasible. Not only that the radiopharmaceutical 
uptake in the pathological conditions depends on the blood supply to the organ, 
bolus injection of the radiopharmaceutical and the functional integrity of the 
organ. When there is increase in blood supply and integral functionality in a lesion 
will lead to focal increase in radiopharmaceutical uptake resulting in the Hot spots. 
In those situations where there is reduction in the blood supply to the organ and 
decreased functional integrity will result in photopenic or photon void lesions. 
Conventionally scintigraphic imagery is being inferred by graphical inspection of 
the photographic imprints and comparing with the known normal distribution 
pattern in the organ of interest.
The advancement of digital scanning technologies have made it easier to mea-
sure the scintillations by quantifying the per pixel counts of the intended regions. In 
addition, the post-processing and PACS transmission characteristics have been the 
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major reason behind the Dicom compatible graphics. The phrase “SCINTIMETRY” 
means the number of scintillations taking place in intended regions in scintigraphic 
imagery that has been covered in the study. Basically, “Scintimetry” is the combined 
term of “Scintillation + Metric”.
2. Scintimetric characterization
The scintillations in a focal hot spot can be counted using Scintimetry. 
Depending upon the method of comparison there are TWO types of Scintimetry:
1. Regional: The process of drawing the region of interest (ROI), picking the 
ROI, and comparing the same with either equivalent or neighboring site on the 
contra lateral part by marking the same region of interest is known as Spatial 
Scintimetry.
2. Temporal: The ROI is drawn above the lesion of interest or the site at a time 
and evaluating the same with a region of interest on the acquired imagery after 
some time from the first study is known as “Time Bound Scintimetry” or the 
scintimetry of same ROI regarding time.
2.1 Regional scintimetry methods
Scintimetric evaluations can be performed with several quantitative approaches. 
Some of the most popular methods are: a. Local Uptake; b. bone soft tissue ratio; c. 
Lesion bone ratio; d. Standardized Uptake Ratio (SUV); and e. Percentage uptake.
a. Local uptake ratio: It is the easiest way to quantify the tracer’s uptake in an ROI 
to determine the count rate calculated in the form of ratio of count rate in a 
region in a closest area in identical image (Rosenthall and Kaye, 1975) [1]. On 
the other hand, it is also possible to use a line profile curve at lesion area (Lentle 
et al., 1977) [2], Figure 1.
b. Lesion Bone (L/B) Ratio: Here, “lesion” means focal region of abnormality and 
“bone” refers to the suitable region of a bone. Its utility has been best described 
by (Condon et al., 1981) [3] and (Vellenga et al., 1984) [4] when it comes to 




Focal Increased Radiopharmaceutical Uptake Differentiation Using Quantitative Indices
DOI: http://dx.doi.org/10.5772/intechopen.99065
c. Bone/Soft Tissue: There are some measurements that can help detect 
hematological malignancies in patients (Pfeifer et al., 1983) [5]. This ratio 
has been used by (Constable and Cranage, 1980) [6] to verify the prostatic 
super scans.
d. Percentage uptake: The uptake is referred in the area of interest to the given 
dose to calculate the percentage uptake (Hardly et al., 1980) [7] or to the given 
external activity by Meindok et al., 1985 [8].
2.2 Methods of temporal scintimetry
There are two methods to do it:
a. Retention Ratio and
b. Change in the regional uptake ratios with reference to time.
• Retention Ratio: Israel et al., 1985 [9] measured Lesion Bone uptake with this 
clue at 4 and 24 hours and suggested that the ratio of 24/4-h was lower among 
patients who have been through metastasis treatment and who have degen-
erative disease. Dr. V. Siva et al., 1995 [10] devised a retention ratio of 4/24 hr. 
to distinguish the focal hotspots into Metabolic, Benign, and Malignant 
characteristics. In that study it has been demonstrated that the Retention 
ratio 0–5 indicates benign nature of the lesion, 5–10 denotes indeterminate or 
metabolic or degenerative nature and 10 and above confirms the malignant 
nature of the lesions. The concept is being depicted in Figure 2.
• Change in Regional uptake ratio: The change in the Regional uptake ratio 
with reference to time is currently used in the evaluation of healing potential 
of Fracture neck of Femur [10].
3. Scintimetric classification of skeletal hot spot in bone scan
X-ray is not sufficient to diagnose bone metastases. Nuclear scintigraphy imag-
ing has always been helpful for early diagnosis of bone disease. The diphosphonates 
Figure 2. 
Dr. V. Siva’s retention ratio.
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labeled as “99mTechnetium” in Bone scan detects the osteoblastic response that 
takes place in malignant cells. This method is best suited for the entire body scan 
at affordable cost and with high sensitivity and availability. But there is a problem 
with specificity [11]. The crystal immature bone surfaces absorb the “99mTc-
polyphosphate” along with its variants through ionic deposition.
The rise in bone vascularity raises this process along with matrix localization. 
Hence, the focal hotspots or abrupt scintiscan area is the region of elevated osteo-
blastic activity. The Scintiscan bone has been shown to be more sensitive than x-rays 
to detect bone’s focal illness. The major flaw in this process is the non-specificity of 
the study [12].
There are reasons Prostatic Carcinoma metastasis, which is usually found in 
bone, has gained a lot of attention for investigation. The anatomical aspects of the 
prostate gland are the first reason. Baston’s plexus is the venous drainage of the 
prostate gland with a unique range of venous plexus. The Lumbosacral plexus of 
veins is directly connected with it. In the advanced stage of prostate cancer, this 
metastatic lesion occurs especially in the axial skeleton [13].
It is not possible to cover the metastatic association in ribs, skull and the bones 
with this anatomical elaboration. According to Paget, there have been mutations 
in carcinoma prostate cells in osteotropic cells either with activation of particular 
proteases and cytokine or with genetic form. They can be latent till an expected 
change takes place around them like a seed. Hence, there is some clue in the ‘seed 
and soil’ theory from the next standpoint [14]. The elevated levels of TGF-β and 
“bone morphogenetic proteins (BMPs)” had been established in metastasis of 
bones in prostate cancer cells [15–18]. These cells of “osteotropic metastatic  
seeds” are combined to the endothelium of bones better than other tissues’  
endothelium [19].
The skeletal tissue contains Tc-99 mm MDP as the ionic radiopharmaceuti-
cal radius is much like the same of “Calcium Hydroxy-appetite crystal”. Hence, 
it is added to the skeletal tissue. Hence, even Osteomyelitis, Paget’s disease and 
Post Traumatic skeletal disorders occur with focal skeletal hotspots. For skeletal 
hotspots, the major cause must be determined with invasive procedure and further 
scanning as well. Several quantitative measures are there to improve the specificity 
of bone scan. Along with fusion imaging procedures like PET-CT and SPECT–CT, 
BONE SPECT and other cross-sectional techniques have been introduced. We have 
proposed a novel Scintimetric technique in this work for bone scanning to verify 
and rule out metastatic or malignant nature of skeletal areas in the non-invasive 
bone imaging.
The bone scans have focal hotspot margins of 4 and 24 h followed by injecting 
radiopharmaceutical drawings with a tool and experts tabulate the maximum per-
pixel counts in such scans. The ratio of two values is taken to determine the focal 
hotspot changes in the scan with time interval. It is defined as Scintimetry of one 
region regarding time and is termed “Time Bound Scintimetry”. In addition, it is 
possible to infer the metabolic turnover in hotspots.
4. Temporal scintimetry method and Dr. Siva’s retention ratio
A method named “Temporal Scintimetry” has been proposed by Israel et al. [9]. 
The Non lesion (NL) and Lesion (L) count ratio has been measured over the bone at 
4 h in bone imaging. It is also performed again in bone scan at 24 h as well.
 “Israel’s ratio L / N 24 h / L / N 4 h”=  (1)
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There has been too negligible variation in measurements among patients who 
have been treated with metastasis and with degenerative disease and it was steep in 
metastatic lesions. The decimal values came up in the result only as the indicator is 
high according to the “Radioactive decay law”. We also presented Dr. V. Siva’s 4/24 h 
retention ratio in this work to classify the ‘focal hot spots’ and to find the difference 
between benign lesions and metastatic lesions with this procedure [10]:
1. Only the maximum counts at the Lesion or Focal hot spot were taken rather 
than L/N ratio.
2. The 4/24 h ratio of Dr. V. Siva is taken rather than Israel’s 24/4 h ratio.
5. Dr. V. Siva’s retention ratio = 4/24 h focal hot spot count
5.1  Clinical applications of scintimetric characterization of the skeletal hotspots 
in the differentiation of benign and metastatic lesion
The bone scan was performed 4 h following the 15–25 mCi of IV injection 
containing “Tc-99 m Methylene Di-Phosphonate “with proper hydration with the 
entire body acquisition of dual head gamma camcorder of Siemen’s eCAM. Next 
day, the full-body bone imaging is done again with the same protocol and injection. 
The General Display protocol is used to select both images of 4 h and 24 h. The 4 h 
anterior and 24 h posterior scans are selected with Region Ratio protocol and the 
experts tabulate the maximum counts at a focal area. The region ratio protocol is 
used to calculate Dr. V. Siva 4/24 h retention ratios and it is also tabulated.
In a study, a group of 32 patients with proven and known Paget’s disease, 
Avascular Necrosis, Osteomyelitis, and degenerative problems and 75 patients 
with proven Carcino Prostate biopsy reports were included. There was metastatic 
involvement in 53 people in a Carcinoma Prostate group, out of which 22 were 
reported negative for metastases. The “11.5 ± 2.8” is the mean value of the 4/24 
retention ratio of Dr. V. Siva in malignant bone lesions and “0.08 ± 0.02” is the 
mean value of Israel’s 24/4 ratio in the group with Carcinoma Prostate. The mean 
value of “4.8 ± 2.5” was found in benign bone lesions in Dr. V Siva’s 4/24 retention 
ratio and “-0.06 ± 0.02” was the mean value of Israel’s 24/4 ratio. The statistical val-
ues are estimated using the online “Social Sciences Statistics” calculator. The T value 
comes out to be 17.1 from the two independent values of the student T test. There 
was a significant result at p <0.05 value and <0.00001 is the p value. There was a 
significant outcome at p <0.05 value. Figure 3 illustrates the graphical calculation 
of dispersion and major difference between metastatic and benign lesions:
Figure 3. 
The graphical representation of difference between A – Benign and B – Malignant lesions.
Radiopharmaceuticals
6
The Quantitative and non-invasive classification of “Skeletal Metastasis” 
with Tc99m MDP scans in Carcinoma prostate was presenting good values with 
Retention Ratio of Dr. V. Siva as per Serum PSA levels [20].
6. Evaluating pathological/non-healing fractures using scintimetry
The authors in [21] have documented the “Scintimetric” assessment of “delayed 
union of skeletal fractures”. The retention values of 4/24 for all cases were charac-
terized into benign fracture and metastatic fracture as per the scientometric clas-
sification of skeletal hot spots. Around 37% (11) were pathological fractures and 
63% (19) were benign ones due to benign bone tumors and stress fracture out of 30 
non-union/delayed skeletal fractures reported. Dr. V. Siva’s 4/24 h retention ratio 
had 12.5 ± 3.1 of mean value for pathological group with typical estimation of ± 0.61 
for errors and the error estimation (±0.38) was measured with mean value “6.68 ± 
2.8” of benign group. The statistical calculation found a major difference between 
two values with <0.0001 of p value.
The authors in [22] also reported the comparative study of Scintimetric classifi-
cation by the “Triple Phase Bone Scan” and Retention Ratio by Dr. V Siva in skeletal 
fracture as compared to the entire body counts. The authors in [23] also described 
the use cases of “scientometric classification of skeletal hotspots” also in a  
diagnostic facility.
7. Scintimetry in rheumatoid arthritis
The bone imaging of two-sided hands is helpful to determine the severity of 
afflictions in interphalangeal joints. The accumulation of delayed 24 h imaging of 
hands and quantitative retention ratio measurements was helpful. The authors in 
[24] also published a groundwork report on Scintimetric assessment of the involve-
ment of rheumatoid arthritis by retention ratio of Dr. V Siva. The mean of “5.91 ± 
0.35” was found in the maximum counts of skeletal zones of patients in 3 h and 24 h 
scans as well as the 4/24 h ratio with means of 0.3496 in standard error. The 8.8408 
was the estimated variance and 2.9734 was the standard and estimated deviation. 
The 6.6306 was the estimated variance for the sample size and 2.575 was the standard 
estimated deviation by modification from HOJO. The sample population was very 
small and it was totally unavoidable. It opens further research paths on a global scale.
8. Diastolic dysfunction assessment, characterization and identification
The left ventricle has the diastolic function that plays an important role in effi-
cacy and preservation of left systolic ventricular function. Hence, there have been a 
lot of concerns on determining the “Left Ventricular Diastolic function” as well as the 
management and detection of left heart failure. The “M-mode echocardiography” is 
usually taken to evaluate the same at the mitral valve orifice with “E/A ratio” tracing. 
The “Left Ventricular Diastolic function” Stage I is represented by <0.8 of E/A ratio, 
Stage II by >1.4, and Stage III by >1.8 [25, 26]. The tissue characterization and “Color 
Doppler echocardiography” are the methods to refine these parameters [27].
The advancement of studies related to “ECG-Gated SPECT” has given 
great insights for its evaluation. The visual insights to “Regional Wall Motion 
Abnormalities” and “Ejection Fraction” with “Gated SPECT Myocardial Perfusion 
Studies” are widely used and popular. However, it is still important to explore 
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the portal to extract and analyze vital info from the analysis of “Phase image” 
of systolic and diastolic phases in cardiac cycle. After the use of “Gated SPECT 
Myocardial Perfusion Imaging” described by Morgan and Mannting [28] in the year 
1993, Raymond Taillefer et al. [29] explained the “Diastolic image analysis” and its 
utility in early diagnosis of C.A.D. among women over “Summed Image Analysis” 
in the year 1999.
A “Gated SPECT Perfusion Processing” protocol has been developed by Siemens 
on the basis of Depuey et al. [30] who have covered individual image analysis 
in “Ejection fraction calculation”, “Diastole and Systole”, and “Regional Wall 
Thickness”. With “phase image analysis” in processing of “Gated SPECT Perfusion”, 
the “Irregular, In-homogenous, and Insufficient Tracer distribution” incidence is 
inferred having regular, homogenous and even tracer distribution in summed scans 
to show diastolic dysfunction. The “SNMICON” presentation [31] also highlights 
the association with the markers of “echocardiographic diastolic dysfunction”, 
especially “Diabetes Mellitus and Hypertension” and E/A ratio.
The ideal correlation between S/D ratio and rate of Peak flow is estimated by con-
sidering the “Time Volume” curves that are obtained from E/A ratio and ECG-gated 
SPECT [32]. The “Time To Peak Flow” and “Peak Flow Rate” are the parameters 
of diastolic dysfunction. Their normal values have been documented to determine 
diastolic function with total agreement between “Echocardiographic assessment and 
QGSPECT” using 16-frame “99mTc-Sestamibi Gated Myocardial Perfusion SPECT” 
[33]. According to RD Lele et al., diastolic dysfunction was 92/121 (76) and “echo-
cardiographic E/A ratio” detected only 53/121 (43%) [29]. The common individual 
risk factor was “Left Ventricular Hypertrophy (LVH)” with heavy risk related to 
unfavorable results [34, 35]. Some of the major causes are hypertension and hyper-
trophic cardiomyopathy (HCM) [36] and aortic stenosis, obesity, and chronic kidney 
problems are responsible for the thickness of the left LV wall [37–40].
There were 75 males aged 31 to 67 years participated in a study to evaluate 
the left “ventricular diastolic dysfunction” with average age of 51.9 ± 7.4 years 
and there were 25 females from 31 to 55 years with mean 45.9 ± 6.6 years of mean 
age. The patients using “Thallum-201 Bruce protocol 2-mCi” on a treadmill were 
injected after exercise with “Gated SPECT MPI” through IV. They were equipped 
with E-Cam Dual Head Gamma cam by Siemens. The “Gated SPECT PERFUSION 
ANALYSIS” protocol was used by the ICON software to analyze the images. The 
irregular, in-homogenous and insufficient tracer distribution was found in diastolic 
phase scans instead of usual Systolic phase scans. These images show changes in 
diastolic dysfunction in “left ventricular muscle tissue” (Figure 4).
Figure 4. 
Diastolic images – Upper row, systolic images middle row, Bull’s eye maps third row.
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The images on the upper row show diastolic phase in various angles. These scans 
show in-homogenous, constantly decreased, irregular, and insufficient distribution 
of tracer, which indicate perfusion absence. The images on the lower row of the 
systolic phase illustrate stable and normal tracer distribution. In this study, the dis-
cordance between systolic and diastolic phases has been displayed and it is related 
to straight changes because of diastolic dysfunction in the “left ventricular muscle 
mass”. These images display Bull’s eye map assessment and ‘left ventricular ejection 
fraction’ of the end systolic perfusion, end diastolic perfusion, and wall thickening. 
The systolic and diastolic phases are described in the images on the lower and upper 
row, respectively. The bull’s eye map of “diastolic phase ED perfusion” describes 
affliction from moderate to severe levels as per the ES perfusion on systolic phase 
and color scale that displays color and normal scale. The left ventricular ejection 
which is calculated from the “end systolic ES volumes” and derived end diastolic 
ED” is normal.
The research findings have been noted as below. The researchers have tabulated 
the echocardiographic grading of “left ventricular diastolic dysfunction” apart  
from the findings given above. They saved the scan data of systolic and diastolic 
pictures in H.L.A., S.A., and V.L.A. views. The inner and outer margins are drawn 
by the “ventricular wall outline” in the systolic and diastolic phase and counts 
were calculated in the area of interest with the ICON software’s region ratio count 
protocol (Figure 5).
The S/D ratio was used to tabulate the diastolic and systolic counts in female and 
male patients in this study. We also analyzed the S/D ratios of diastolic dysfunction 
stage II and Stage III individually. We found the discordance between systolic and 
diastolic pictures in 98/100 (98%). The Grade II and Grade III classify the echo-
cardiographic images of this disorder with E/A ratio in 87/100 (87%). Similarly, 
hypertension was reported in 63% and diabetes in only 16%. There was no major 
statistical change in S/D ratio between both groups (Figure 6).
The Grade II LVDD has 1.47 ± 0.32 of S/D ratio and Grade III LVDD has 1.81 ± 
0.03 of S/D ratio. With “Paired Student t-test”, the statistical data found a major 
difference between Stage II and Stage III in S/D ratio (Figure 7).
The visual analysis of the images of systolic and diastolic phases led to inter-
pretation and identification of heart’s “Left ventricular diastolic dysfunction”. This 
method identified 98% (98/100) people with this condition. On the other hand, 
the E/A echocardiographic test detected only 87% of patients. The direct changes 
Figure 5. 
Scintimetric method of calculating Distolic and systolic for deriving S/D ratio.
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in “Left ventricular cardiac myocytes” base the visual analysis to diagnose diastolic 
dysfunction. Hence, they could detect 98% of cases with diastolic dysfunction. RD 
Lele et al. [34] detected only 76% (92/121) cases with diastolic heart function by 
using “16-Gated Myocardial Perfusion SPECT” and “time volume curve” analysis.
On the other side, diastolic dysfunction is detected in 98% patients with “direct 
visual image interpretative assessment” of systolic and diastolic phases. However, 
there is a need to extend this study further to all the rest of “Gated SPECT” research 
for a large number of patients. It is also important to contemplate the separated 
comparison of ES and ED perfusions in both rest and stress gated myocardial imag-
ing results. Along with it, the normal population should also be included as this 
study group covered only patients.
Figure 6. 
No difference between A-male and B-female scintimetric S/D values.
Figure 7. 
Significant difference between A-stage II and B-stage III scintimetric S/D values.
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9.  Scintimetric characterization of primary tumors by dual phase 
PETCT study
The utility and advantage of the dual phase PETCT evaluation in the tumor detec-
tion was reported by Kuboto K et al. [41]. The optimal time interval between the early 
and delayed phase PETCT scans had been proved to be 3 hr. post injection by Chen 
YM et al. [42]. In our study protocol the delayed PETCT was conducted at 4 hours 
post injection due to logistic reasons. Rong et al. reported a quantitative estimation 
to differentiate between the benign and malignant bone lesions using the dual phase 
PETCT evaluation termed as Rong’s Retention Index [43]. The Rong’s retention index 
(RRI), computed as follows:
 RRI = (SUVmaxD-SUVmaxE)X 100  (2)
Even though there is a noticeable difference between the malignant and benign 
bone lesions, they also have a major overlap in between.
 
Dr.V.Siva’s modified Retention ratio  SUV max Delayed 
/  SUV max Early X 100
=
 (3)
We have focused on the clinical and technical aspects of a novel method in this 
oncologic utility of “Positron Emission Tomography (PET)”. In this method, the 
PET scanner is combined with a CT scanner in a single device [44–47].
In May 2019, this study was conducted among 19 patients aged 9 to 76 years (12 
females, 7 males) with a median of 46 ± 18 years with active primary and metabolically 
lesions of several types of cancers. Permission was taken from each volunteer before 
they joined the study for delayed 4 h PET/CT scan without injecting F18-FDG any 
further. The protocol of “F-18 FDG PET image reconstruction and acquisition” was 
approved by the ethics group and all cases have obtained official consent.
Patients did not drink or eat anything for 4 to 6 hours before IV injection of 
“F-18 FDG (185 to 375 MBq, i.e. 4 MBq/kg of weight of the body)”. Before getting 
injected, patients received the concentration of serum glucose and all patients had 
glucose levels below 200 mg/dl. After the injection at 1 hour early and PET/CT 
scans at 4 hour (delayed) after injection with PET/CT scanner (from PETCT and 
Wipro GE), the patients settled down in a silent room. The Spiral CT was used for 
acquiring CT image at 0.75 s per rotation with 4 mm of section thickness, 4 mm of 
interval, and 40mAs and 120 kVp.
No IV contrast injection was used. We obtained the early images of PET emis-
sion from thigh to cranium, usually with 6–7 positions with acquisition of 2 minutes 
in each bed position. We acquired the images of delayed PET emission of abnormal 
spots at 4 h after F-18 FDG injection, with 2 minutes of interval between 2 to 
3 bed positions. We used the LOR algorithm to reconstruct all PET scans while 
applying CT-based correction of attenuation. We used the “Advantage 4.7 Volume 
Viewer“program to obtain the images. The F-18 FDG uptake was evaluated with 
delayed and early PET images, evaluation of parameters and interpretation of PET 
image, semi quantitatively. A circular ROI was positioned above the detected bone 
lesion for semi-quantitative analysis with transverse PET picture.
The ROI was positioned above the whole “F18 FDG lesion” for visualized lesions 
on PET, including utmost radioactivity. The following formula was used to estimate 
the “Standardized Uptake Value”:
 
( ) ( ) ( )“SUV tissue concentration / g /[injected dose / body weight g ”= MBq MBq
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For each region of interest, the SUVmax or maximal SUV was calculated in 
lesion ROI. The variations in the lesions’ uptake were measured as retention index:
 ( )“RI SUVmaxD SUVmaxE 100 / SUVmaxE”= - ´  (4)
Here is the formula to calculate RRI modification by Dr. V. Siva:
 “RRI SUVmaxD / SUVmaxE 100”= ´  (5)
The dual time point based quantifications of metabolic uptake rate in 18F-FDG 
PET had been reported by den Hoff et al. [48]. The potential diagnostic role of 
dual phase 18F-FDG PETCT scanning was reported by Jones c et al. [49]. This is the 
first study reporting the findings of the dual phase PETCT in the evaluation and 
characterization in various primary lesions. The Rong’s Retention values showed a 
wide ranging value and no definite cut off value could be arrived at. But Dr. V. Siva’s 
modification of Rong’s Retention Ratio revealed that the cut off value to be 100 and 
above for confirming the malignant nature of the lesions. The statistical evaluation 
of the values by Student t Test showed good p value confirming the significance that 
the two values were significantly different. There is a strong positive correlation in 
the “Pearson evaluation”. It means a high y variable with high x scores and vice versa 
(Figure 8). The inclusion of the various primary malignancies in both the sexes 
adds advantage to the study. However the non-inclusion of primary benign lesions 
in the study is the greatest disadvantage. The other limitations being the single 
institutional study and the small number of patient population.
Scintimetric Characterization of metastatic lymph nodes in various primary 
malignancies by Dual Phase PETCT study.
In the proven cases of various primary malignancies like Ca. Breast, Ca. Prostate, 
Lymphomas and alveolar tumors the SUV max values of the metastatic lymph nodes 
were calculated in both the Early and Delayed phase scans. The PETCT study was 
performed using the GE Discovery IQ PETCT in those patients with positive lymph 
node uptake. The early scan was done One hour post injection of 5 to 10 mCi of F18-
FDG tracer in the fasting state with their informed consent with optimal serum blood 
Figure 8. 
Pearson correlation coefficient test.
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sugar level of 150 mg/dl. The delayed PETCT was done Four hours after the post 
injection time with voluntary consent of the patients without any additional injection 
of the tracer or contrast medium. The SUV max values were obtained utilizing the 
Advantage 4.4 software provided by the GE. Total of Forty eight lymph nodes at vari-
ous locations were included in the study. The calculated SUV max values were used to 
arrive at the Rong’s Retention Ratio and the Dr. V. Siva’s modification of RRI.
The Rong’s retention ratio in the Metastatic lymph nodes group showed the 
mean value of 37.2 ± 17.0. Dr. V. Siva’s modification of the Rong’s Ratio showed the 
mean value of 132.7 ± 19.8. The Dr. V. Siva’a modification of Rong’s Retention ratio 
resulted in the increase in value by 100 with no significant overlap.
In the previous study of dual PETCT scintimentric characterization of the 
various primary malignancies the Rong’s Retention ratio showed the mean value 
of 35.8 ± 8 and the Dr. V. Siva’s modification of RRI showed the mean value of 
135 ± 8.1 as reported confirming that the definitive cut of value of 100 and above 
could be assigned to indicate the malignant and metastatic lesions in the Dual 
Phase PETCT scans in the Dr. V. Siva’s modification method. By eliminating 
the subtraction of early SUV max value from the delayed SUV max value the 
negative values were avoided. The statistical analysis of the data using student t 
test evaluation showed that there is clear cut demarcation between the original 
Rong’s Retention Ratio values and the Dr. V. Siva’s modification of Rong’s Ratio as 
shown in the Figure 9.
The p value is < 0.0001 indicating the validity of Dr. V. Siva’s modification of 
Rong’s Ratio in the Scintimetric characterization of the metastatic lymph nodes of 
various primary cancers. However the homogeneous population of cancer patients 
and non-inclusion of the benign lymph nodal enlargement is a definitive limita-
tion of this study. Further evaluation of this concept is warranted as this is a single 
institutional study of short duration and small number of cases.
10. Conclusions
The Scintimetric Characterization of the skeletal hot spots helps in the differen-
tiation of benign and malignant lesions that might coexist in a carcinoma prostate 
patient and treat them accordingly. This has been proved to be useful in the assess-
ment of non healing fractures and pathological fractures as well. The usefulness of 
this in the evaluation of Rheumatoid Arthritis opens up a new era of research on 
clinical utilization in both the diagnostic and prognostic aspects of the disease pro-
cess. The identification and characterization of the diastolic dysfunction directly by 
applying the Systolic/Diastolic count ration in the gated SPECT myocardial viability 
studies remains to be explored further.
Figure 9. 
The difference between group 1 Rong’s ratio group 2 Dr. V. Siva’s modification.
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The advent and quantification of FDG uptake in a hot spot in the Dual Phase 
PETCT scan helps in the identification and differentiation of various primary 
malignant processes and the Metastatic involvement of the lymph nodes. The clini-
cal application of the quantitative indices like the Israel’s ratio, Dr. V. Siva’s retention 
ratio in the conventional nuclear medicine studies must see the light of clinical 
utilization of day to day practice. Similarly in the case of PETCT evaluation of 
Oncology the utilization of the Rong’s retention ratio and the Dr. V. Siva’s modifica-
tion of Rong’s Ratio should reach the daily practice mode from the bench [50–52].
11. Future perspectives
In the current era of large volume Data handling and DATAMATIC scenario this 
quantitative approach will be more suitable for the QBOT establishment for qualita-
tive standardization of the Nuclear Medicine studies [53]. These quantitative indices 
can be incorporated into the automatic report generation aspect of the Artificial 
Intelligence in Nuclear medicine as reported by Cumali Aktolun and Felix Nensa 
[54, 55]. The recent explosion in DATA sciences and ARTIFICIAL INTELLIGENCE 
provide a new arena worth exploring in the future.
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